To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV
Phase 4
Completed
- Conditions
- Reaction - VaccineVaccination
- Interventions
- Biological: Sabin-IPV+Sabin-IPV+bOPVBiological: Sabin-IPV+Sabin-IPV+Sabin-IPVBiological: Sabin-IPV+bOPV+bOPV
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- China National Biotec Group Company Limited
- Target Recruit Count
- 604
- Registration Number
- NCT04054492
- Locations
- 🇨🇳
Inner Mongolia Autonomous Region Center for Diseases Prevention and Control, Hohhot, Inner Mongolia Autonomous Region, China
Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP
Phase 4
Completed
- Conditions
- Vaccination
- Interventions
- Biological: Sabin-IPV and DTaPBiological: Sabin-IPVBiological: DTaP
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- China National Biotec Group Company Limited
- Target Recruit Count
- 702
- Registration Number
- NCT04054882
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP
Phase 4
- Conditions
- Vaccination
- Interventions
- Biological: Sabin-IPV and DTaPBiological: Sabin-IPVBiological: DTaP
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- China National Biotec Group Company Limited
- Target Recruit Count
- 702
- Registration Number
- NCT04053010
- Locations
- 🇨🇳
Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, Shaanxi, China
Immunogenicity and Safety of Sabin-IPV Replacement Vaccination
Phase 4
Completed
- Conditions
- Vaccination
- Interventions
- Biological: Inactivated Polio Vaccine
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- China National Biotec Group Company Limited
- Target Recruit Count
- 360
- Registration Number
- NCT04051736
- Locations
- 🇨🇳
Beijing Center for Disease Control and Prevention, Beijing, Beijing, China
Comparative Immunogenicity Study of Two Hepatitis A Vaccines
Phase 4
- Conditions
- Hepatitis A
- Interventions
- Biological: Hepatitis A Vaccine
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- China National Biotec Group Company Limited
- Target Recruit Count
- 300
- Registration Number
- NCT03231605
- Locations
- 🇨🇳
Shanxi Provincial Center for Disease Control and Prevention, Yuncheng, Shanxi, China
© Copyright 2025. All Rights Reserved by MedPath